<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2183-6914</journal-id>
<journal-title><![CDATA[Revista Onconews]]></journal-title>
<abbrev-journal-title><![CDATA[Revista Onconews]]></abbrev-journal-title>
<issn>2183-6914</issn>
<publisher>
<publisher-name><![CDATA[Associação de Enfermagem Oncológica Portuguesa (AEOP)]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2183-69142021000100056</article-id>
<article-id pub-id-type="doi">10.31877/on.2021.42.07</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Subvalorização das artralgias: papel do enfermeiro na detecção precoce da imunotoxicidade.]]></article-title>
<article-title xml:lang="en"><![CDATA[Undervaluation of arthralgies: role of nurses in early immunotoxicity detection.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[Catarina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chemela]]></surname>
<given-names><![CDATA[Raquel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Português de Oncologia de Lisboa Unidade de Técnicas de Pneumologia ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Português de Oncologia de Lisboa Hospital de Dia Quimioterapia ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>30</day>
<month>06</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>06</month>
<year>2021</year>
</pub-date>
<numero>42</numero>
<fpage>56</fpage>
<lpage>62</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S2183-69142021000100056&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S2183-69142021000100056&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S2183-69142021000100056&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo Os Inibidores do Checkpoint Imunitário (ICI) revolucionaram o tratamento oncológico. Os efeitos adversos da imunoterapia decorrentes da administração dos inibidores do checkpoint imunitário podem ser graves e potencialmente fatais. Embora a maioria das toxicidades seja bem estudada e sobejamente relatada, as complicações reumatológicas são menos reconhecidas e caracterizadas. Descreve-se um estudo de caso em que tanto Performance Status como a qualidade de vida (QdV) de um doente foram afetados pela imunotoxicidade reumatológica bem como o papel do enfermeiro na sua deteção precoce e os cuidados de enfermagem prestados de forma a minimizar o seu impacto na QdV.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract The use of immune checkpoint inhibition (ICI) has revolutionized cancer treatment. However, these medications are associated with significant and potentially debilitating immune-related adverse events or even life threathing. While the majority of toxicities have been well studied, rheumatic complications have been less widely recognized and characterized. We describe a case study in which both performance status and quality of life of a patient where affected by rheumatological toxicity as wells the nurses&#8217; role in the early recognition and toxicity&#8217; management in order to enhance the patient&#8217; quality of life.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Imunoterapia]]></kwd>
<kwd lng="pt"><![CDATA[reações adversa]]></kwd>
<kwd lng="en"><![CDATA[Immunotherapy]]></kwd>
<kwd lng="en"><![CDATA[checkpoint inhibitors]]></kwd>
<kwd lng="en"><![CDATA[immune-related adverse events]]></kwd>
<kwd lng="en"><![CDATA[rheumatic and musculoskeletal diseases]]></kwd>
<kwd lng="en"><![CDATA[arthralgias]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ABDEL-WAHAB]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[SUAREZ-ALMAZOR]]></surname>
<given-names><![CDATA[M.E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2019</year>
<volume>58</volume>
<page-range>vii40-8</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ARANDA]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[JEFFORD]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[YATES]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of a novel nurse-led prechemotherapy education intervention (ChemoEd) on patient distress, symptom burden, and treatment-related information and support needs: results from a randomised, controlled trial]]></article-title>
<source><![CDATA[Ann OncoL]]></source>
<year>2012</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>222-31</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BENFAREMO]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[MANFREDI]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[LUCHETTI]]></surname>
<given-names><![CDATA[M.M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature]]></article-title>
<source><![CDATA[Curr Drug Saf]]></source>
<year>2018</year>
<volume>13</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>150-64</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BRAHMER]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[LACCHETTI]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[SCHNEIDER]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology(ASCO) clinical practice guideline]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2018</year>
<volume>36</volume>
<page-range>1714-68</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="">
<collab>BRITISH GERIATRICS SOCIETY</collab>
<source><![CDATA[Fit for Frailty - Consensus best practice guidance for the care of older people living in community and outpatient settings]]></source>
<year>2017</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BROENS]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
<name>
<surname><![CDATA[HUIS IN&#8217;T VELD]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[VOLLENBROEK-HUTTEN]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Determinants of successful telemedicine implementations: a literature study]]></article-title>
<source><![CDATA[J Telemed Telecare]]></source>
<year>2007</year>
<volume>13</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>303-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BUTCHER]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
<name>
<surname><![CDATA[BULECHEK]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[DOCHTERMAN]]></surname>
<given-names><![CDATA[JMM]]></given-names>
</name>
</person-group>
<source><![CDATA[Nursing Interventions Classification (NIC)]]></source>
<year>2018</year>
<edition>7</edition>
<publisher-name><![CDATA[Elsevier Health Sciences]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CAPPELLI]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[GUTIERREZ]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[BINGHAM]]></surname>
<given-names><![CDATA[CO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature]]></article-title>
<source><![CDATA[Arthritis Care Res]]></source>
<year>2017</year>
<volume>69</volume>
<page-range>1751_63</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CHAMPIAT]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[LAMBOTTE]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[BARREAU]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2016</year>
<volume>27</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>559-74</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ELIAS]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[MORALES]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[PRESLEY]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Checkpoint Inhibitors for Non-Small Cell Lung CancerAmong Older Adults]]></article-title>
<source><![CDATA[Curr Oncol Rep]]></source>
<year>2017</year>
<volume>19</volume>
<page-range>62</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[FABIÃO]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Pessoa com doença oncológica: Re(encontro com a qualidade de vida]]></source>
<year>2004</year>
<publisher-name><![CDATA[Instituto de Ciencias Biomedicas de Abel Salazar, Universidade do Porto]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HAANEN]]></surname>
<given-names><![CDATA[JBAG]]></given-names>
</name>
<name>
<surname><![CDATA[CARBONNEL]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[ROBERT]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2017</year>
<volume>28</volume>
<numero>Suppl 4</numero>
<issue>Suppl 4</issue>
<page-range>iv119-42</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HENDERSON]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<source><![CDATA[Princípios básicos de enfermagem da CIE]]></source>
<year>2007</year>
<edition>1</edition>
<publisher-loc><![CDATA[Portugal ]]></publisher-loc>
<publisher-name><![CDATA[Lusodidacta]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HURRIA]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[MOHILE]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[GAJRA]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validation of a prediction tool for chemotherapy toxicity in older adults with cancer]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2016</year>
<volume>34</volume>
<page-range>2366-U104</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[JAMAL]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[HUDSON]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[FIFI-MAH]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist]]></article-title>
<source><![CDATA[J Rheumatol]]></source>
<year>2020</year>
<volume>47</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>166-75</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MCILFATRICK]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[SULLIVAN]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[MCKENNA]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patients&#8217; experiences of having chemotherapy in a day hospital setting]]></article-title>
<source><![CDATA[J Adv Nurs]]></source>
<year>2007</year>
<volume>59</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>264-73</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MELISSAROPOULOS]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[KLAVDIANOU]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[FILIPPOPOULOU]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2020</year>
<volume>21</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>3389</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MOORADIAN]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[NASRALLAH]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[GAINOR]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: a single center experience]]></article-title>
<source><![CDATA[Semin Arthritis Rheum]]></source>
<year>2018</year>
<volume>48</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1127-32</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[NORONHA]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[SEKHAR]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[VIJAY]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic therapy for limited stage small cell lung carcinoma]]></article-title>
<source><![CDATA[J Thorac Dis]]></source>
<year>2020</year>
<volume>12</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>6275-90</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PAREDES]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[SIMÕES]]></surname>
<given-names><![CDATA[M.R.]]></given-names>
</name>
<name>
<surname><![CDATA[CANAVARRO]]></surname>
<given-names><![CDATA[M.C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impacto da Doença Cronica na Qualidade de Vida: comparação entre indivíduos da população geral e doente com tumor no aparelho locomotor]]></article-title>
<source><![CDATA[Psicologia, Saúde e Doença]]></source>
<year>2008</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>73-87</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[POSTOW]]></surname>
<given-names><![CDATA[M A]]></given-names>
</name>
<name>
<surname><![CDATA[SIDLOW]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[HELLMANN]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immune-related adverse events associated with immune checkpoint blockade]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2018</year>
<volume>378</volume>
<page-range>158-68</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[STEVEN]]></surname>
<given-names><![CDATA[N. M.]]></given-names>
</name>
<name>
<surname><![CDATA[FISHER]]></surname>
<given-names><![CDATA[B. A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2019</year>
<volume>58</volume>
<page-range>vii29-39</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="">
<collab>US Department of Health and Human Services</collab>
<source><![CDATA[Common Terminology Criteria for Adverse Events (CTCAE) version 5.0]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[WANG]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[CHEN]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[SONG]]></surname>
<given-names><![CDATA[S Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis]]></article-title>
<source><![CDATA[JAMA Oncology]]></source>
<year>2017</year>
<volume>18</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>730</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
